CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk
Data from AiKidney Helps Clinicians Gain New Insights into Patient’s Risk of Allograft Rejection
This follows CareDx’s recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV). Presentations covering these developments will occur during the 2022
AiKidney delivers information about a patient’s current risk of rejection and a prognosis of allograft survival at three, five, and seven years. AiKidney can be used for informing clinical management decisions and to help clinicians predict the long-term impact of treatments. As transplant patient care becomes more complex, with an increasing focus on optimizing immunosuppression and long-term care, AlloSure is the only donor-derived cell-free DNA (dd-cfDNA) solution that features this additive AI-enabled risk assessment algorithm.
“CareDx is driving the next wave of transplant innovation with multimodality that amplifies the power of AlloSure by incorporating artificial intelligence.2 AiKidney has the potential to set a new standard of care through precision medicine by generating new insights to support earlier interventions or to modulate immunosuppression when assessing the risk of rejection by physicians,” said
“We’re proud to work with
“Studies have shown the effectiveness of CareDx’s multimodality solutions for routine kidney transplant surveillance and for identifying immune-quiescence,”3-5 said
Transplant Congress Presentations Highlight the Utility of AI-Enabled Risk Assessments:
CareDx Product Theatre: The Predictive Powerof AlloSure and AiKidney, Sunday, June 5, 9:30–10:00 am ET, Theatre A, Exhibit Hall C
CareDx Lunch Symposium: A Window to a
New World: Multi-Modality Molecular Characterization & Prediction of Allograft Outcomes, Tuesday, June 7, 12:45 – 1:45pm ET.
For detailed agendas for the product theatre and lunch symposium, please go to the
CareDx Innovation Day:
Artificial Intelligence in Transplantation and CareDx Clinical Pipeline,
Tuesday, June 7, 2:00 -3:00pm ET. The event will be held in a hybrid format to enable a wide audience to participate. To learn more and sign up, register here.
Long-term kidney transplant failure is a serious issue and begins to accelerate three years post-transplantation. Kidney failure rates6 are approximately 15 percent at three years, 21 percent at five years and 48 percent at ten years.7 Graft injury and rejection are the main reasons for transplant failures, excluding death. Adding to the problem is a serious kidney organ shortage. Over 90,000 Americans are on the waiting list for a kidney transplant, and about 13 people die each day waiting for one.8 Conventional kidney transplant biomarkers (e.g. serum creatine) are lagging indicators of kidney transplant rejection. Innovations from
Note: The product theater, symposium, and investor innovation day are not part of the official
Forward Looking Statements
This press release includes forward-looking statements related to
The product theaters, symposium, and investor innovation day are not part of the official
American Transplant Congress(ATC) educational program, and the sessions and content are not endorsed by ATC.
Aubert O, Brousse R,
Juliette Gueguen J, et al. FC 113: Development and Validation of an Integrative DD-CFDNA System to Predict Allograft Rejection: A Population Based Study, Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May 2022, gfac123.002, https://doi.org/10.1093/ndt/gfac123.002
Bu L, Gupta G, Pai A, et al, Validation and clinical outcome in assessing donor-derived cell freeDNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study.,
Kidney International(2022), doi: https://doi.org/10.1016/j.kint.2021.11.034.
Cheung R, Xu H, Jin X, et al. Validation of a gene expression signature to measure immune quiescence in kidney transplant recipients in the CLIA setting. Biomarkers in Medicine. Published Online:
29 Apr 2022. https://doi.org/10.2217/bmm-2022-0113
Akalin E, Weir MR, Bunnapradist S, et al. Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. Kidney360.
December 2021, 2 (12) 1998-2009; DOI: https://doi.org/10.34067/KID.0005062021
- Deceased kidney organ donations.
- Hart A, Lentine KL, Smith JM,et al. OPTN/SRTR 2019 Annual Data Report: Kidney. Am J Transplant. 2021 Feb;21 Suppl 2:21-137. doi: 10.1111/ajt.16502. PMID: 33595191.
UNOS Website. https://www.srtr.org/reports/optnsrtr-annual-data-report/ accessed
May 30 2022
Chief Marketing Officer